These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35728714)

  • 1. Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum β-lactamase (ESBL)-producing versus non-ESBL-producing Escherichia coli in a hollow-fibre infection model.
    Islam K; Sime FB; Bauer MJ; Forde BM; Wallis SC; Harris P; Naicker S; Shirin T; Habib ZH; Flora MS; Roberts JA
    Int J Antimicrob Agents; 2022 Aug; 60(2):106623. PubMed ID: 35728714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
    Islam K; Sime FB; Wallis SC; Bauer MJ; Forde BM; Harris P; Shirin T; Habib ZH; Flora MS; Roberts JA
    J Antimicrob Chemother; 2022 Aug; 77(9):2448-2455. PubMed ID: 35724128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.
    Islam K; Sime FB; Wallis SC; Bauer MJ; Naicker S; Won H; Zowawi HM; Choudhury MA; Shirin T; Habib ZH; Harris PNA; Flora MS; Roberts JA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0016222. PubMed ID: 35924928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Escherichia coli clinical isolates.
    Sumi CD; Heffernan AJ; Naicker S; Cottrell K; Wallis SC; Lipman J; Harris PNA; Sime FB; Roberts JA
    J Antimicrob Chemother; 2022 Oct; 77(11):3026-3034. PubMed ID: 36031790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
    Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
    Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
    Rodríguez-Villodres Á; Gutiérrez Linares A; Gálvez-Benitez L; Pachón J; Lepe JA; Smani Y
    Microbiol Spectr; 2021 Oct; 9(2):e0080121. PubMed ID: 34668721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
    Hertz FB; Andreasen MR; Almind SR; Nielsen KL; Hansen KH; Jelsbak L; Frimodt-Møller N; Schønning K
    Int J Antimicrob Agents; 2022 Apr; 59(4):106543. PubMed ID: 35134504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.
    Suzuki Y; Sato T; Fukushima Y; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
    Int J Antimicrob Agents; 2020 Apr; 55(4):105919. PubMed ID: 32062000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.
    Abdelraouf K; Chavda KD; Satlin MJ; Jenkins SG; Kreiswirth BN; Nicolau DP
    Int J Antimicrob Agents; 2020 Mar; 55(3):105885. PubMed ID: 31923568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae.
    Sumi CD; Heffernan AJ; Naicker S; Islam K; Cottrell K; Wallis SC; Lipman J; Harris PNA; Sime FB; Roberts JA
    J Antimicrob Chemother; 2020 Sep; 75(9):2633-2640. PubMed ID: 32585693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.
    Schechter LM; Creely DP; Garner CD; Shortridge D; Nguyen H; Chen L; Hanson BM; Sodergren E; Weinstock GM; Dunne WM; van Belkum A; Leopold SR
    mBio; 2018 Apr; 9(2):. PubMed ID: 29691340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Cefotaxime-Resistant Escherichia coli Isolates from Healthy Cattle and Sheep in Northern Spain: Phenotypic and Genome-Based Characterization of Antimicrobial Susceptibility.
    Tello M; Ocejo M; Oporto B; Hurtado A
    Appl Environ Microbiol; 2020 Jul; 86(15):. PubMed ID: 32471914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V
    Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli.
    Livermore DM; Day M; Cleary P; Hopkins KL; Toleman MA; Wareham DW; Wiuff C; Doumith M; Woodford N
    J Antimicrob Chemother; 2019 Feb; 74(2):326-333. PubMed ID: 30388219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation of beta-lactamase genes and clonal relationship among the extended-spectrum beta-lactamase producing nosocomial Escherichia coli isolates].
    Görgeç S; Kuzucu Ç; Otlu B; Yetkin F; Ersoy Y
    Mikrobiyol Bul; 2015 Jan; 49(1):15-25. PubMed ID: 25706727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.